- Recent Funding
- Investors
- Tri Locum Partners
Tri Locum Partners portfolio
Tri Locum Partners has 1 portfolio company on record at Recent Funding. Its most recent investment on record is Geneoscopy's $105M Series B+ round in January 2025, alongside Varia Ventures, SINC Fund, Petrichor Healthcare Capital Management and 6 others. That company is in Health and bio.
What Tri Locum Partners invests in
- Health and bio · 1 · 100%
How Tri Locum Partners invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series B+ | 1 100% | $105M |
Share is of the 1 round on Recent Funding that name Tri Locum Partners. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Tri Locum Partners portfolio companies
GGeneoscopy$105MSeries B+ · Jan 2025
| Company | Round with Tri Locum Partners | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ · $105M | $216.9M | Jan 8, 2025 Series B+ |
Most frequent co-investors
- VVaria Ventures1 shared round · last Jan 8, 2025
- SSINC Fund1 shared round · last Jan 8, 2025
- PPetrichor Healthcare Capital Management1 shared round · last Jan 8, 2025
- NNT Investments1 shared round · last Jan 8, 2025
MMorningside1 shared round · last Jan 8, 2025
MMercy1 shared round · last Jan 8, 2025
LLightchain Capital1 shared round · last Jan 8, 2025
LLabCorp1 shared round · last Jan 8, 2025
GGranger Management LLC1 shared round · last Jan 8, 2025
Similar investors
AAccelia Capital1 company · 1 deal in 12 mo
BBioGenerator Ventures1 company · 1 deal in 12 mo
BBiospring Partners1 company · 1 deal in 12 mo
CColossa Ventures1 company · 1 deal in 12 moFFirst Imagine!1 company · 1 deal in 12 mo
MMaxis1 company · 1 deal in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
Portfolio companies are the companies on Recent Funding with a round that lists Tri Locum Partners, which is a subset of its real portfolio. API: /api/v1/investors/tri-locum-partners (get a free API key). More: the most active VC firms and new venture capital funds.